Key Drivers
- Cash Cushion
- Weak Revenue
- Share Dilution
AIAI Summary
CLDX is now a narrow, high-binary-risk bet on barzolvolimab in CSU rather than a broad pipeline story, because the PN miss showed efficacy doesn't automatically transfer, while its $717.6M cash balance gives time but not validation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Cushion
- •Weak Revenue
- •Share Dilution
CLDX has a very strong liquidity position and low leverage, but its investment case is weighed down by minimal revenue, persistent operating losses, negative cash flow, and dilution risk.
Price Behavior
Key Price Behavior Insights:
- •Higher highs
- •Low-40s support
- •Fast pullback
CLDX remains in a constructive uptrend over the last month, with higher highs/lows intact, but near-term upside depends on holding the $41.0–$41.7 support area and reclaiming $44.87 resistance after a brief pullback.
Rapid climb from the mid-$30s to the mid-$40s, followed by a short pullback from $44.87 to $41.95
Sentiment & News
Key News Insights:
- •PN trial failure
- •Program narrowing
- •Institutional accumulation
CLDX faces a major setback after barzolvolimab failed in prurigo nodularis and was dropped from that program, while better-than-expected EPS and a big institutional buy offer some offset.
The clinical miss is the main negative driver for CLDX, but late-stage urticaria focus and recent institutional buying may help support sentiment
Similar Companies in Healthcare
Other companies in the same sector with AI ratings